BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE: KG) announced today the U.S. Food and Drug Administration (FDA) approval of the Company’s new state-of-the-art manufacturing and production facility in Rochester, Michigan for its Bicillin® product line. Bicillin® L-A (penicillin G benzathine injectable suspension) is the first product available from this facility.
